Article
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
The oncologist - 1 Apr 2014
Hanaizi Zahra, Unkrig Christoph, Enzmann Harald, Camarero Jorge, Sancho-Lopez Arantxa, Salmonson Tomas, Gisselbrecht Christian, Laane Edward, Pignatti Francesco
Abstract excerpt
On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (Bosulif) for the treatment of adult patients with chronic-phase, accelerated-phase, and blast-phase Philadelphia chromosome positive (Ph⁺) chronic myelogenous leukemia (CML) previously treated with one tyrosine kinase inhibitor or more and for whom imatinib, nilotinib, and dasatinib are not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.